These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 15994108)
1. In vivo efficiency of targeted norfloxacin against persistent, isoniazid-insensitive, Mycobacterium bovis BCG present in the physiologically hypoxic mouse liver. Balazuc AM; Lagranderie M; Chavarot P; Pescher P; Roseeuw E; Schacht E; Domurado D; Marchal G Microbes Infect; 2005 Jun; 7(7-8):969-75. PubMed ID: 15994108 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin. Roseeuw E; Coessens V; Balazuc AM; Lagranderie M; Chavarot P; Pessina A; Neri MG; Schacht E; Marchal G; Domurado D Antimicrob Agents Chemother; 2003 Nov; 47(11):3435-41. PubMed ID: 14576099 [TBL] [Abstract][Full Text] [Related]
3. Targeted norfloxacin is active in vivo against persistent Mycobacterium bovis BCG. Domurado D; Balazuc AM; Lagranderie M; Pescher P; Chavarot P; Roseeuw E; Coessens V; Stern S; Schacht E; Marchal G J Control Release; 2005 Jan; 101(1-3):343-5. PubMed ID: 15838943 [No Abstract] [Full Text] [Related]
4. Protective effect of beta-glucan against mycobacterium bovis, BCG infection in BALB/c mice. Hetland G; Løvik M; Wiker HG Scand J Immunol; 1998 Jun; 47(6):548-53. PubMed ID: 9652822 [TBL] [Abstract][Full Text] [Related]
5. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of susceptibility of Mycobacterium bovis to antituberculous drugs by radiometric BACTEC 460TB system. Cavirani S; Fanti F; Benecchi M; Calderaro A; Taddei S; Arcangeletti C; Medici MC; Dettori G; Chezzi C New Microbiol; 2003 Apr; 26(2):181-6. PubMed ID: 12737201 [TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomics reveals novel insights into isoniazid susceptibility in mycobacteria mediated by a universal stress protein. Hu X; Li X; Huang L; Chan J; Chen Y; Deng H; Mi K J Proteome Res; 2015 Mar; 14(3):1445-54. PubMed ID: 25664397 [TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. Khan A; Sarkar S; Sarkar D Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548 [TBL] [Abstract][Full Text] [Related]
9. Resistance of various strains of mycobacteria to killing by activated macrophages in vivo. Orme IM; Collins FM J Immunol; 1983 Sep; 131(3):1452-4. PubMed ID: 6411817 [TBL] [Abstract][Full Text] [Related]
10. Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. Watts MR; Taylor PC; Sintchenko V; Whelan CM; Farnsworth RH; Jones P; Jelfs P; Carr D; Goldberg H Clin Infect Dis; 2011 Jan; 52(1):86-8. PubMed ID: 21148524 [TBL] [Abstract][Full Text] [Related]
11. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Budha NR; Lee RB; Hurdle JG; Lee RE; Meibohm B Tuberculosis (Edinb); 2009 Sep; 89(5):378-85. PubMed ID: 19748318 [TBL] [Abstract][Full Text] [Related]
12. [Influence of isoniazid complex with A-I apolipoprotein on activity of lysosomal enzymes in mice with tuberculous inflammation model]. Sumenkova DV; Poliakov LM; Panin LE Eksp Klin Farmakol; 2012; 75(11):28-30. PubMed ID: 23323330 [TBL] [Abstract][Full Text] [Related]
14. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. Taneja NK; Tyagi JS J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560 [TBL] [Abstract][Full Text] [Related]
15. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors. Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902 [TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. Bhakta S; Besra GS; Upton AM; Parish T; Sholto-Douglas-Vernon C; Gibson KJ; Knutton S; Gordon S; DaSilva RP; Anderton MC; Sim E J Exp Med; 2004 May; 199(9):1191-9. PubMed ID: 15117974 [TBL] [Abstract][Full Text] [Related]
17. Primary isoniazid resistance in Mycobacterium bovis disease: a prospect of concern. McLaughlin AM; Gibbons N; Fitzgibbon M; Power JT; Foley SC; Hayes JP; Rogers T; Keane J Am J Respir Crit Care Med; 2012 Jul; 186(1):110-1. PubMed ID: 22753693 [No Abstract] [Full Text] [Related]
18. Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. Beamer G; Major S; Das B; Campos-Neto A Am J Pathol; 2014 Dec; 184(12):3170-5. PubMed ID: 25451154 [TBL] [Abstract][Full Text] [Related]
19. Dielectrophoretic characterization of antibiotic-treated Mycobacterium tuberculosis complex cells. Inoue S; Lee HB; Becker AL; Weigel KM; Kim JH; Lee KH; Cangelosi GA; Chung JH Anal Bioanal Chem; 2015 Oct; 407(25):7673-80. PubMed ID: 26231690 [TBL] [Abstract][Full Text] [Related]
20. Immunocytochemical analysis of cellular responses to BCG. Nibbering PH; van der Heide GA; van Furth R Clin Exp Immunol; 1989 Jan; 75(1):147-54. PubMed ID: 2649284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]